WuXi Biologics (Cayman) Inc
HKEX:2269
Relative Value
The Relative Value of one
WuXi Biologics (Cayman) Inc
stock under the Base Case scenario is
29.71
HKD.
Compared to the current market price of 37.16 HKD,
WuXi Biologics (Cayman) Inc
is
Overvalued by 20%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
WuXi Biologics (Cayman) Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
150.5B HKD | 6.7 | 31.9 | 22.3 | 22.3 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.2T USD | 411.6 | 4 876.1 | 1 430 | 2 872.9 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
218.9B USD | 4.9 | 32.7 | 22.5 | 30.2 | |
| US |
|
Danaher Corp
NYSE:DHR
|
157.5B USD | 6.4 | 43.7 | 24.1 | 36.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81T KRW | 14.7 | 50.7 | 29.8 | 39.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.8B CHF | 5.6 | 38.4 | 28.2 | 28.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
39.4B USD | 2.5 | 30.7 | 14.8 | 22.2 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
271B CNY | 6.1 | 18.1 | 18.2 | 18.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.2B USD | 5.5 | 29.4 | 21.4 | 25.4 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.2B USD | 7.2 | 33.9 | 24.4 | 27.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
22.4B USD | 7.3 | 34.8 | 22.5 | 28 |